Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTXQYT6)

• DTT Name: T-cells (T-cells)
• Synonyms: T cells
• Gene Name: T-cells
• DTT Type: Clinical trial target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T01232

Molecular Interaction Atlas (MIA) of This DTT

8 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ATG-Fresenius S	DM4VJ5Q	Transplant rejection	NE84	Phase 3	[2]
Baltaleucel-T	DM3WCL4	Diffuse large B-cell lymphoma	2A81	Phase 2	[3]
DiabeCell	DMK6FYR	Insulin-dependent diabetes	5A10	Phase 2	[1]
T2c-001	DM06GDC	Congestive heart failure	BD10	Phase 2	[1]
TVI-Kidney-1	DMGYSZ0	Renal cell carcinoma	2C90	Phase 2	[4]
BPX-501	DMIMA4V	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[3]
AX-024	DMRQ32K	Multiple sclerosis	8A40	Phase 1	[5]
RTL-1000	DM1B4CQ	Multiple sclerosis	8A40	Phase 1	[6]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Clinical pipeline report, company report or official report of Neovii Biotech.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of TVAX Biomedical.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] RTL THERAPY FOR MULTIPLE SCLEROSIS: A Phase I Clinical Study. J Neuroimmunol. 2011 February; 231(1-2): 7-14.